retatrutide clinical trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II Wegovy competitor retatrutide shows promise

These experiments were conducted in accordance with the ARRIVE guidelines

Gut microbiota dysbiosis impaired GLP-1 responsiveness (117)

And the avoidance of injection could improve adherence in long-term treatment protocols

CV safety of treatment with tirzepatide in patients with T2D compared to dulaglutide is to be investigated in the SURPASS-CVOT phase III clinical trial scheduled to finish in 2024 (89)

Rybelsus uses SNAC absorption technology and has been studied in multiple clinical trials demonstrating meaningful weight loss

Staying well-hydrated and using simple comfort measures like sugar-free gum or humidifiers speed up this adjustment